# Basiliximab Treating Interstitial Pneumonia of CADM

> **NCT03192657** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Lung; Disease, Interstitial, With Fibrosis
- Dermatomyositis

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Calcineurin Inhibitors
- **DRUG:** Steroids

## Key facts

- **NCT ID:** NCT03192657
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07
- **Primary completion:** 2019-06
- **Final completion:** 2020-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192657, "Basiliximab Treating Interstitial Pneumonia of CADM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03192657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*